Asset Details
Do you wish to reserve the book?
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
Do you wish to request the book?
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
2022
Overview
Objectives
To evaluate the correlation between liver enhancement on hepatobiliary phase and liver function parameters in a multicenter, multivendor study.
Methods
A total of 359 patients who underwent gadoxetic acid–enhanced MRI using a standardized protocol with various scanners within a prospective multicenter phase II trial (SORAMIC) were evaluated. The correlation between liver enhancement on hepatobiliary phase normalized to the spleen (liver-to-spleen ratio, LSR) and biochemical laboratory parameters, clinical findings related to liver functions, liver function grading systems (Child-Pugh and Albumin-Bilirubin [ALBI]), and scanner characteristics were analyzed using uni- and multivariate analyses.
Results
There was a significant positive correlation between LSR and albumin (rho = 0.193;
p
< 0.001), platelet counts (rho = 0.148;
p
= 0.004), and sodium (rho = 0.161;
p
= 0.002); and a negative correlation between LSR and total bilirubin (rho = −0.215;
p
< 0.001) and AST (rho = −0.191;
p
< 0.001). Multivariate analysis confirmed independent significance for each of albumin (
p
= 0.022), total bilirubin (
p
= 0.045), AST (
p
= 0.031), platelet counts (
p
= 0.012), and sodium (
p
= 0.006). The presence of ascites (1.47 vs. 1.69,
p
< 0.001) and varices (1.55 vs. 1.69,
p
= 0.006) was related to significantly lower LSR. Similarly, patients with ALBI grade 1 had significantly higher LSR than patients with grade 2 (1.74 ± 0.447 vs. 1.56 ± 0.408,
p <
0.001); and Child-Pugh A patients had a significantly higher LSR than Child-Pugh B (1.67 ± 0.44 vs. 1.49 ± 0.33,
p
= 0.021). Also, LSR was negatively correlated with MELD-Na scores (rho = −0.137;
p
= 0.013). However, one scanner brand was significantly associated with lower LSR (
p
< 0.001).
Conclusions
The liver enhancement on the hepatobiliary phase of gadoxetic acid–enhanced MRI is correlated with biomarkers of liver functions in a multicenter cohort. However, this correlation shows variations between scanner brands.
Key Points
• The correlation between liver enhancement on the hepatobiliary phase of gadoxetic acid–enhanced MRI and liver function is consistent in a multicenter-multivendor cohort.
• Signal intensity–based indices (liver-to-spleen ratio) can be used as an imaging biomarker of liver function.
• However, absolute values might change between vendors.
